These results emphasize the importance of developing a combined therapy targeting caspase‐1 activity while enhancing IL‐18 production to reverse glucose and lipid alterations associated with obesity. This evidence concerns the gene IL18 and obesity due to melanocortin 4 receptor deficiency.